Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 2 |
| Global Hepatitis Market - Introduction | 8 | 2 |
| GBI Research Report Guidance | 9 | 1 |
| Global Hepatitis Market - Market Overview | 10 | 13 |
| Introduction | 10 | 2 |
| Global Hepatitis Therapeutics and Vaccines Market | 12 | 1 |
| Revenue Forecasts for the Global Hepatitis Therapeutics Market | 13 | 1 |
| Revenue | 13 | 1 |
| Annual Cost of Therapy | 14 | 1 |
| Treatment Usage Patterns | 15 | 2 |
| Diseased Population | 17 | 1 |
| Treatment Seeking Population | 18 | 1 |
| Diagnosed Population | 19 | 1 |
| Prescription Population | 20 | 1 |
| Hepatitis Market Drivers | 21 | 1 |
| Hepatitis C is a Growing Market with Strong Competition and a Promising Pipeline | 21 | 1 |
| Promising Developments in Hepatitis C Pipeline | 21 | 1 |
| Steady Increase in Prescription Population | 21 | 1 |
| Hepatitis Market Restraints | 21 | 1 |
| Hepatitis Rarely Recognized during the Early Stages of the Disease | 21 | 1 |
| Low Treatment Seeking Population | 21 | 1 |
| Loss of Exclusivity Protection in Hepatitis B Market | 21 | 1 |
| Generic Share in the Global Hepatitis Therapeutics Market | 22 | 1 |
| Global Hepatitis Market - Therapeutic Landscape | 23 | 22 |
| Introduction | 23 | 1 |
| Hepatitis A | 23 | 1 |
| Hepatitis B | 23 | 1 |
| Hepatitis C | 24 | 1 |
| Overview of Hepatitis A and B Vaccines Market | 25 | 1 |
| Revenue | 25 | 1 |
| Hepatitis B Therapeutics Market | 26 | 1 |
| Revenue | 26 | 1 |
| Annual Cost of Therapy | 27 | 1 |
| Treatment Usage Patterns | 28 | 1 |
| Diseased Population | 29 | 1 |
| Treatment Seeking Population | 30 | 1 |
| Diagnosed Population | 31 | 1 |
| Prescription Population | 32 | 1 |
| Geographical Segmentation | 33 | 2 |
| Hepatitis C Therapeutics Market | 35 | 1 |
| Revenue | 35 | 1 |
| Annual Cost of Therapy | 36 | 1 |
| Treatment Usage Pattern | 37 | 2 |
| Diseased Population | 39 | 1 |
| Treatment Seeking Population | 40 | 1 |
| Diagnosed Population | 41 | 1 |
| Prescription Population | 42 | 1 |
| Geographical Segmentation | 43 | 2 |
| Global Hepatitis Market - Geographical Landscape | 45 | 27 |
| Geographical Break-up | 45 | 2 |
| The US Hepatitis Therapeutics Market | 47 | 1 |
| Revenue | 47 | 1 |
| Annual Cost of Therapy | 47 | 1 |
| Treatment Usage Patterns | 48 | 3 |
| Diseased Population | 51 | 1 |
| Treatment Seeking Population | 52 | 1 |
| Diagnosed Population | 53 | 1 |
| Prescription Population | 54 | 1 |
| Top Five Countries in Europe Hepatitis Therapeutics Market | 55 | 1 |
| Revenue | 55 | 2 |
| Annual Cost of Therapy | 57 | 1 |
| Treatment Usage Patterns | 58 | 2 |
| Diseased Population | 60 | 1 |
| Treatment Seeking Population | 61 | 1 |
| Diagnosed Population | 62 | 1 |
| Prescription Population | 63 | 1 |
| Japan Hepatitis Therapeutics Market | 64 | 1 |
| Revenue | 64 | 1 |
| Annual Cost of Therapy | 65 | 1 |
| Treatment Usage Patterns | 66 | 2 |
| Diseased Population | 68 | 1 |
| Treatment Seeking Population | 69 | 1 |
| Diagnosed Population | 70 | 1 |
| Prescription Population | 71 | 1 |
| Global Hepatitis Market - Pipeline Analysis | 72 | 23 |
| Introduction | 72 | 2 |
| Research and Development Pipeline - Hepatitis A Vaccines | 74 | 1 |
| Research and Development Pipeline - Hepatitis B Therapeutics | 75 | 4 |
| Research and Development Pipeline - Hepatitis B Vaccines | 79 | 2 |
| Research and Development Pipeline - Hepatitis C Therapeutics | 81 | 9 |
| Molecule Profile for Promising Vaccines for Hepatitis B under Clinical Development | 90 | 1 |
| Heplisav | 90 | 1 |
| Overview | 90 | 1 |
| Efficacy | 90 | 1 |
| Safety | 90 | 1 |
| Clinical Study Details | 90 | 1 |
| Spi-VEC | 90 | 1 |
| Overview | 90 | 1 |
| Efficacy | 90 | 1 |
| Safety | 90 | 1 |
| Clinical Study Details | 91 | 1 |
| Molecule Profile for Promising Therapeutics for Hepatitis B under Clinical Development | 91 | 1 |
| Entecavir plus Adefovir Combination Therapy | 91 | 1 |
| Overview | 91 | 1 |
| Efficacy | 91 | 1 |
| Safety | 91 | 1 |
| Clinical Study Details | 91 | 1 |
| Tenofovir plus Emtricitabine Combination Therapy | 91 | 1 |
| Overview | 91 | 1 |
| Efficacy | 91 | 1 |
| Safety | 91 | 1 |
| Clinical Study Details | 91 | 1 |
| Pegylated Interferon Alfa-2a + Adefovir | 92 | 1 |
| Overview | 92 | 1 |
| Efficacy | 92 | 1 |
| Safety | 92 | 1 |
| Clinical Study Details | 92 | 1 |
| Molecule Profile for Promising Therapeutics for Hepatitis C under Clinical Development | 92 | 1 |
| Tenofovir + Emtricitabine Combination Therapy | 92 | 1 |
| Introduction | 92 | 1 |
| Clinical Trial Management | 92 | 1 |
| Zalbin (albinterferon alfa-2b, Joulferon) | 92 | 1 |
| Introduction | 92 | 1 |
| Mechanism of Action | 93 | 1 |
| Clinical Trial Management | 93 | 1 |
| RG 7128 | 94 | 1 |
| Introduction | 94 | 1 |
| Mechanism of Action | 94 | 1 |
| Clinical Trial Management | 94 | 1 |
| Global Hepatitis Market - Competitive Landscape | 95 | 7 |
| Market Share Analysis: Hepatitis | 95 | 2 |
| Competitive Profiling | 97 | 1 |
| Merck &Co., Inc. | 97 | 1 |
| SWOT Analysis | 97 | 1 |
| Product Portfolio | 97 | 2 |
| F. Hoffmann-La Roche Ltd. | 99 | 1 |
| SWOT Analysis | 99 | 1 |
| Product Portfolio | 99 | 1 |
| GlaxoSmithKline plc | 100 | 1 |
| SWOT Analysis | 100 | 1 |
| Product Portfolio | 101 | 1 |
| Global Hepatitis Market - Strategic Consolidations | 102 | 7 |
| Mergers and Acquisitions | 102 | 1 |
| Overview | 102 | 1 |
| Deals by Geography | 102 | 1 |
| Deals by Type | 103 | 1 |
| Summary of M&A Deals (2010-2011) | 104 | 1 |
| Kadmon Pharmaceuticals Acquires Three Rivers Pharmaceuticals | 104 | 1 |
| Johnson &Johnson Acquires Crucell | 104 | 1 |
| Biovail Acquires Valeant Pharmaceuticals | 104 | 1 |
| Bristol-Myers Squibb Acquires ZymoGenetics | 104 | 1 |
| Calzada Acquires Minority Stake in Avexa | 104 | 1 |
| R&D Licensing Agreements | 105 | 1 |
| Summary of Licensing Deals (2010-2011) | 105 | 1 |
| Cyplasin Biomedical Enters into Licensing Agreement with Virionics | 105 | 1 |
| Valeant Pharmaceuticals Enters into Licensing Agreement with Kadmon for Taribavirin | 105 | 1 |
| Ligand Enters into Licensing Agreement with Chiva for Pradefovir and MB01733 | 106 | 1 |
| Vertex Pharmaceuticals Enters into Licensing Agreement with Alios BioPharma for ALS-2200 and ALS-2158 | 106 | 1 |
| Achillion Pharmaceuticals Enters into Licensing Agreement with GCA Therapeutics | 106 | 1 |
| Debiopharm Enters into Licensing Agreement with Novartis | 106 | 1 |
| Medivir Enters into Licensing Agreement with Daewoong Pharmaceutical | 107 | 1 |
| GenMark Diagnostics Enters into Licensing Agreement with Innogenetics | 107 | 1 |
| Hanmi Pharmaceutical Enters into Licensing Agreement with Whail Pharmaceuticals | 107 | 1 |
| Compass Biotechnologies Enters into Licensing Agreement with Arecor | 107 | 1 |
| Co-Development Deals | 108 | 1 |
| Global Hepatitis Market - Appendix | 109 | 6 |
| Market Definitions | 109 | 1 |
| Abbreviations | 109 | 1 |
| Research Methodology | 110 | 2 |
| Coverage | 110 | 1 |
| Secondary Research | 110 | 1 |
| Primary Research | 111 | 1 |
| Therapeutic Landscape | 111 | 3 |
| Epidemiology-Based Forecasting | 112 | 1 |
| Market Size by Geography | 113 | 1 |
| Geographical Landscape | 114 | 1 |
| Pipeline Analysis | 114 | 1 |
| Competitive Landscape | 114 | 1 |
| Expert Panel Validation | 114 | 1 |
| Contact Us | 114 | 1 |
| Disclaimer | 114 | 1 |